Ixazomib (BioDeep_00000654256)
代谢物信息卡片
Ixazomib
化学式: C14H19BCl2N2O4 (360.0814864)
中文名称: 艾沙佐米
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
InChI: InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1
描述信息
A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XG - Proteasome inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2160 - Proteasome Inhibitor
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
D000970 - Antineoplastic Agents
C471 - Enzyme Inhibitor
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:90942
- KEGGdrug: D10130
- PubChem: 25183872
- DrugBank: DB09570
- ChEMBL: CHEMBL2141296
- CAS: 1072833-77-2
- MetaboLights: MTBLC90942
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Huixian Chen, Yongjing Wang, Chunchun Shao, Chenxi Sun, Chengyun Zheng. Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis.
Hematology (Amsterdam, Netherlands).
2021 Dec; 26(1):1031-1039. doi:
10.1080/16078454.2021.2009648. [PMID: 34895096] - Apor Hardi, Gergely Varga, Zsolt Nagy, Szabolcs Kosztolányi, László Váróczy, Márk Plander, Tamás Schneider, Judit Demeter, Hussain Alizadeh, Árpád Illés, Tamás Masszi, Gábor Mikala. Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime.
Orvosi hetilap.
2021 09; 162(36):1451-1458. doi:
10.1556/650.2021.32179. [PMID: 34482291] - Srikanth R Polusani, Valerie Cortez, Javier Esparza, Huynh Nga Nguyen, Hongxin Fan, Gopalrao V N Velagaleti, Matthew J Butler, Marsha C Kinney, Babatunde O Oyajobi, Samy L Habib, Reto Asmis, Edward A Medina. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
International journal of cancer.
2021 06; 148(12):3032-3040. doi:
10.1002/ijc.33497. [PMID: 33521927] - Gary Schwartz, Kevin Shee, Bianca Romo, Jonathan Marotti, Alexei Kisselev, Lionel Lewis, Todd Miller. Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.
The oncologist.
2021 06; 26(6):467-e924. doi:
10.1002/onco.13733. [PMID: 33641211] - Fengbo Jin, Mingzhen Yang, Yingying Chen, Lei Jiang, Lixia Liu. Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
Medicine.
2020 Nov; 99(45):e22632. doi:
10.1097/md.0000000000022632. [PMID: 33157919] - Jing Li, Li Bao, Zhongjun Xia, Sili Wang, Xin Zhou, Kaiyang Ding, Wenhao Zhang, Wei Yang, Bingzong Li, Chengcheng Fu, Bing Chen, Luoming Hua, Liang Wang, Jun Luo, Yang Yang, Tianhong Xu, Weida Wang, Yun Huang, Guolin Wu, Peng Liu. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Annals of hematology.
2020 Nov; 99(11):2589-2598. doi:
10.1007/s00277-020-04234-9. [PMID: 32892275] - Samantha Hinsley, Katrina Walker, Debbie Sherratt, Lucy Bailey, Sadie Reed, Louise Flanagan, Sophie McKee, Fiona Brudenell Straw, Bryony Dawkins, David Meads, Holger W Auner, Martin F Kaiser, Mark Cook, Sarah Brown, Gordon Cook. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Trials.
2020 Oct; 21(1):826. doi:
10.1186/s13063-020-04739-8. [PMID: 33008427] - Saurabh Chhabra, Alexis Visotcky, Marcelo C Pasquini, Fenlu Zhu, Xiaoying Tang, Mei-Jie Zhang, Robert Thompson, Sameem Abedin, Anita D'Souza, Binod Dhakal, William R Drobyski, Timothy S Fenske, James H Jerkins, J Douglas Rizzo, Lyndsey Runaas, Wael Saber, Nirav N Shah, Bronwen E Shaw, Mary M Horowitz, Parameswaran N Hari, Mehdi Hamadani. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2020 10; 26(10):1876-1885. doi:
10.1016/j.bbmt.2020.07.005. [PMID: 32653622] - Evangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, Jiri Minarik, Ioannis Ntanasis-Stathopoulos, Eirini Katodritou, Matthew W Jenner, Hana Plonkova, Maria Gavriatopoulou, Grant D Vallance, Tomas Pika, Maria Kotsopoulou, Jaimal Kothari, Tomas Jelinek, Efstathios Kastritis, Robin Aitchison, Meletios A Dimopoulos, Athanasios Zomas, Roman Hajek. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Annals of hematology.
2020 May; 99(5):1049-1061. doi:
10.1007/s00277-020-03981-z. [PMID: 32236735] - Sofia Pizzato Scomazzon, Anna Riccio, Silvia Santopolo, Giulia Lanzilli, Marta Coccia, Antonio Rossi, M Gabriella Santoro. The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Molecular cancer research : MCR.
2019 12; 17(12):2444-2456. doi:
10.1158/1541-7786.mcr-19-0243. [PMID: 31540997] - Neeraj Gupta, Michael J Hanley, Cindy Xia, Richard Labotka, R Donald Harvey, Karthik Venkatakrishnan. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
Clinical pharmacokinetics.
2019 04; 58(4):431-449. doi:
10.1007/s40262-018-0702-1. [PMID: 30117017] - Hyun Mi Kang, Kyung Hee Noh, Tae Kyung Chang, Dongmin Park, Hyun-Soo Cho, Jung Hwa Lim, Cho-Rok Jung. Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma.
Cell death & disease.
2019 03; 10(4):279. doi:
10.1038/s41419-019-1520-6. [PMID: 30902965] - Sandeepraj Pusalkar, Mihaela Plesescu, Neeraj Gupta, Michael Hanley, Karthik Venkatakrishnan, Jing-Tao Wu, Cindy Xia, Xiaoquan Zhang, Swapan Chowdhury. Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces.
Cancer chemotherapy and pharmacology.
2018 11; 82(5):803-814. doi:
10.1007/s00280-018-3671-z. [PMID: 30128949] - Neeraj Gupta, Steven Zhang, Sandeepraj Pusalkar, Mihaela Plesescu, Swapan Chowdhury, Michael J Hanley, Bingxia Wang, Cindy Xia, Xiaoquan Zhang, Karthik Venkatakrishnan, Dale R Shepard. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
Investigational new drugs.
2018 06; 36(3):407-415. doi:
10.1007/s10637-017-0509-1. [PMID: 28932928] - Nisha S Joseph, Jonathan L Kaufman. Novel Approaches for the Management of AL Amyloidosis.
Current hematologic malignancy reports.
2018 06; 13(3):212-219. doi:
10.1007/s11899-018-0450-1. [PMID: 29951831] - Alina Striha, A John Ashcroft, Anna Hockaday, David A Cairns, Karen Boardman, Gwen Jacques, Cathy Williams, John A Snowden, Mamta Garg, Jamie Cavenagh, Kwee Yong, Mark T Drayson, Roger Owen, Mark Cook, Gordon Cook. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Trials.
2018 Mar; 19(1):169. doi:
10.1186/s13063-018-2524-8. [PMID: 29514706] - Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Alberto Bessudo, Drew W Rasco, Sunil Sharma, Bert H O'Neil, Bingxia Wang, Guohui Liu, Alice Ke, Chirag Patel, Karen Rowland Yeo, Cindy Xia, Xiaoquan Zhang, Dixie-Lee Esseltine, John Nemunaitis. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Journal of clinical pharmacology.
2018 02; 58(2):180-192. doi:
10.1002/jcph.988. [PMID: 28800141] - Massimo Offidani, Laura Corvatta, Silvia Gentili. Triplet vs. doublet drug regimens for managing multiple myeloma.
Expert opinion on pharmacotherapy.
2018 02; 19(2):137-149. doi:
10.1080/14656566.2017.1418856. [PMID: 29265901] - Masaki Ri. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2018 ; 59(10):2162-2168. doi:
10.11406/rinketsu.59.2162. [PMID: 30305522] - Marco Salvini, Rossella Troia, Davide Giudice, Chiara Pautasso, Mario Boccadoro, Alessandra Larocca. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Expert opinion on drug metabolism & toxicology.
2018 Jan; 14(1):91-99. doi:
10.1080/17425255.2018.1417388. [PMID: 29235380] - Neeraj Gupta, Paul M Diderichsen, Michael J Hanley, Deborah Berg, Helgi van de Velde, R Donald Harvey, Karthik Venkatakrishnan. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Clinical pharmacokinetics.
2017 11; 56(11):1355-1368. doi:
10.1007/s40262-017-0526-4. [PMID: 28290121] - Yanmei Yang, Hong Lei, Ya-Wei Qiang, Bin Wang. Ixazomib enhances parathyroid hormone-induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor.
Molecular biology of the cell.
2017 Jul; 28(13):1792-1803. doi:
10.1091/mbc.e17-02-0096. [PMID: 28495797] - Ahmad Samer Al-Homsi, Austin Goodyke, Kelli Cole, Marlee Muilenburg, Michael McLane, Sarah Abdel-Mageed, Yuxin Feng. Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.
Experimental hematology.
2017 04; 48(?):50-57. doi:
10.1016/j.exphem.2016.12.002. [PMID: 28007655] - Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Bingxia Wang, Sunil Sharma, Alberto Bessudo, Ai-Min Hui, John Nemunaitis. The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Journal of clinical pharmacology.
2016 10; 56(10):1288-95. doi:
10.1002/jcph.719. [PMID: 26872892] - Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Raymond Perez, Robin E Norris, John Nemunaitis, Huyuan Yang, Mark G Qian, Gerald Falchook, Richard Labotka, Siqing Fu. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
British journal of clinical pharmacology.
2016 09; 82(3):728-38. doi:
10.1111/bcp.12991. [PMID: 27121262] - Neeraj Gupta, Michael J Hanley, R Donald Harvey, Ashraf Badros, Brea Lipe, Vishal Kukreti, Jesus Berdeja, Huyuan Yang, Ai-Min Hui, Mark Qian, Xiaoquan Zhang, Karthik Venkatakrishnan, Ajai Chari. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
British journal of haematology.
2016 Sep; 174(5):748-59. doi:
10.1111/bjh.14125. [PMID: 27196567] - Neeraj Gupta, Richard Labotka, Guohui Liu, Ai-Min Hui, Karthik Venkatakrishnan. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Investigational new drugs.
2016 06; 34(3):338-46. doi:
10.1007/s10637-016-0346-7. [PMID: 27039387] - Hao Wang, Yang Yu, Zheng Jiang, Wen-Ming Cao, Zhenyu Wang, Jun Dou, Yanling Zhao, Yunfu Cui, Hong Zhang. Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Scientific reports.
2016 05; 6(?):26456. doi:
10.1038/srep26456. [PMID: 27217076] - Jonghoon Park, Eok Park, Cheol-Kyu Jung, Seung-Wan Kang, Byung Gyu Kim, Youngjoo Jung, Tae Hun Kim, Ji-Young Lim, Sung-Eun Lee, Chang-Ki Min, Kwang-Ai Won. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
BMC cancer.
2016 Mar; 16(?):247. doi:
10.1186/s12885-016-2285-2. [PMID: 27012957] - Neeraj Gupta, Yeow Tee Goh, Chang-Ki Min, Jae Hoon Lee, Kihyun Kim, Raymond S M Wong, Chor Sang Chim, Michael J Hanley, Huyuan Yang, Karthik Venkatakrishnan, Ai-Min Hui, Dixie-Lee Esseltine, Wee Joo Chng. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Journal of hematology & oncology.
2015 Sep; 8(?):103. doi:
10.1186/s13045-015-0198-1. [PMID: 26337806] - Neeraj Gupta, Yeamin Huh, Matthew M Hutmacher, Sean Ottinger, Ai-Min Hui, Karthik Venkatakrishnan. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Cancer chemotherapy and pharmacology.
2015 Sep; 76(3):507-16. doi:
10.1007/s00280-015-2815-7. [PMID: 26141494] - Shannon R Reese, Nancy A Wilson, Gengwen Huang, Robert R Redfield, Weixiong Zhong, Arjang Djamali. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Transplantation.
2015 Sep; 99(9):1785-95. doi:
10.1097/tp.0000000000000736. [PMID: 25919767] - David C Smith, Thea Kalebic, Jeffrey R Infante, Lillian L Siu, Daniel Sullivan, Gordana Vlahovic, John S Kauh, Feng Gao, Allison J Berger, Stephen Tirrell, Neeraj Gupta, Alessandra Di Bacco, Deborah Berg, Guohui Liu, Jianchang Lin, Ai-Min Hui, John A Thompson. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Investigational new drugs.
2015 Jun; 33(3):652-63. doi:
10.1007/s10637-015-0230-x. [PMID: 25777468] - Nibedita Chattopadhyay, Allison J Berger, Erik Koenig, Bret Bannerman, James Garnsey, Hugues Bernard, Paul Hales, Angel Maldonado Lopez, Yu Yang, Jill Donelan, Kristen Jordan, Stephen Tirrell, Bradley Stringer, Cindy Xia, Greg Hather, Katherine Galvin, Mark Manfredi, Nelson Rhodes, Ben Amidon. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
PloS one.
2015; 10(12):e0144825. doi:
10.1371/journal.pone.0144825. [PMID: 26709701] - S E Assouline, J Chang, B D Cheson, R Rifkin, S Hamburg, R Reyes, A-M Hui, J Yu, N Gupta, A Di Bacco, Y Shou, P Martin. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Blood cancer journal.
2014 Oct; 4(?):e251. doi:
10.1038/bcj.2014.71. [PMID: 25325301] - Paul G Richardson, Rachid Baz, Michael Wang, Andrzej J Jakubowiak, Jacob P Laubach, R Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Sagar Lonial. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Blood.
2014 Aug; 124(7):1038-46. doi:
10.1182/blood-2014-01-548826. [PMID: 24920586] - Massimo Offidani, Laura Corvatta, Patrizia Caraffa, Silvia Gentili, Laura Maracci, Pietro Leoni. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.
OncoTargets and therapy.
2014; 7(?):1793-800. doi:
10.2147/ott.s49187. [PMID: 25302026] - Edmund C Lee, Michael Fitzgerald, Bret Bannerman, Jill Donelan, Kristen Bano, Jennifer Terkelsen, Daniel P Bradley, Ozlem Subakan, Matthew D Silva, Ray Liu, Michael Pickard, Zhi Li, Olga Tayber, Ping Li, Paul Hales, Mary Carsillo, Vishala T Neppalli, Allison J Berger, Erik Kupperman, Mark Manfredi, Joseph B Bolen, Brian Van Ness, Siegfried Janz. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011 Dec; 17(23):7313-23. doi:
10.1158/1078-0432.ccr-11-0636. [PMID: 21903769]